Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep ...

Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep ...

Vivos Therapeutics Inc (NASDAQ:VVOS) shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of ...

Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering.

LITTLETON, Colo. - Vivos Therapeutics, Inc. (NASDAQ: VVOS), a company specializing in treatments for sleep-related breathing disorders, announced today that the American Medical... ByInvesting.com ...

(MENAFN- Investor Brand Network) Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company specializing in the development and commercialization of highly effective proprietary treatments ...

Short interest in Vivos Therapeutics Inc (NASDAQ:VVOS) increased during the last reporting period, rising from 56.86K to 63.71K. This put 2.57% of the company's publicly available shares short.

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 9.6% of Vivos Therapeutics shares are owned ...

Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of ...

Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Oil & Gas, Technology and Basic Materials sectors led shares higher. At the close in NYSE, the ...

Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly ...